5/9/2025

AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries.AM Best has affirmed the Financial Strength Rating of A and the Long-Term Issuer Credit Ratings of 'a' of Aetna...

Source: Finnhub

5/9/2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Source: Yahoo

5/8/2025

OLDWICK, N.J., May 08, 2025--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) [NYSE: CVS]. (Please see below for a detailed listing of the companies.)

Source: Yahoo

5/8/2025

Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.

Source: Yahoo

5/8/2025

Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.

Source: Yahoo

5/8/2025

DENTSPLY SIRONA's customer-centric innovation and operational efficiency drive its first-quarter 2025 performance despite global macroeconomic challenges.

Source: Yahoo

5/8/2025

Shareholders appeared unconcerned with CVS Health Corporation's ( NYSE:CVS ) lackluster earnings report last week. Our...

Source: Yahoo

5/8/2025

Source: SeekingAlpha

5/8/2025

We added new holdings in the industrials, health care and energy sectors, purchases that were funded by sales across several different sectors, including one IT holding.

Source: SeekingAlpha

5/8/2025

The Perils of Medicare Drug Coverage

Source: MarketWatch

5/7/2025

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings, including its global position in the GLP-1 weight-loss drug space and its partnership with CVS Health (CVS). Catch Anjalee Khemlani's full interview with Novo Nordisk CEO Lars Jørgensen. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Source: Yahoo

5/7/2025

We recently published a list of Jim Cramer Reveals Trump’s Potential Secret Weapon In China Trade Talks & Discusses These 10 Stocks. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on […]

Source: Yahoo

5/7/2025

COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.

Source: Yahoo

5/7/2025

Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.

Source: Yahoo

5/7/2025

Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.

Source: Yahoo

5/7/2025

Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.

Source: Yahoo

5/7/2025

Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.

Source: Yahoo

5/7/2025

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures came out to a total of $11.9 billion, falling in line with Wall Street estimates. Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's partnership and price goals with CVS Health (CVS), and the company's outlook on its US manufacturing position and President Trump's proposed pharmaceutical tariffs. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Source: Yahoo

5/7/2025

CVS stock has an attractive yield and earnings expansion. That makes it worth a look for investors seeking growth and income.

Source: Yahoo

5/7/2025

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Source: Yahoo